Recursion Pharmaceuticals (RXRX) Common Equity (2020 - 2026)

Recursion Pharmaceuticals has reported Common Equity for 7 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 9.72% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 9.72% YoY), and the FY2025 full-year result was $1.1 billion, up 9.29% from the prior year.
• Common Equity for Q1 2026 stood at $1.0 billion, down from $1.1 billion in the prior quarter.
• The five-year high for Common Equity was $1.1 billion in Q4 2025, with the low at $388.0 million in Q3 2022.
• Historically, Common Equity has averaged $659.2 million across 5 years, with a median of $493.6 million in 2022.
• The largest YoY upside for Common Equity was 311.8% in 2022 against a maximum downside of 35.22% in 2022.
• Recursion Pharmaceuticals' Common Equity stood at $485.8 million in 2022, then dropped by 4.6% to $463.4 million in 2023, then soared by 123.28% to $1.0 billion in 2024, then grew by 9.29% to $1.1 billion in 2025, then fell by 9.38% to $1.0 billion in 2026.
• The last three Common Equity figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.